Ajanta Pharma Ltd. Duloxetine Delayed-Release Capsules, 60 mg recall: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.
The hazard: Potency, impurity or stability failure
The recall concerns the strength or purity of the medicine rather than contamination of it, which changes what you should do about a dose you have already taken.
What the notice says: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.
Why it matters: The product failed a specification test: it may contain more or less active ingredient than the label states, carry an impurity, or degrade before its expiry date. A sub-potent dose can leave a condition untreated; a super-potent one can cause an overdose.
Symptoms and when to call a doctor
The risk depends entirely on the drug. For a medicine where dose matters closely — a blood thinner, an anti-epileptic, a thyroid or heart medicine, insulin — talk to your prescriber before changing anything. Seek urgent care if you have symptoms that suggest too much drug, or if the condition the medicine controls starts breaking through.
This page is general information, not medical advice. If you feel unwell, a clinician who can see you is the only person able to judge your case.
Recall details
- Recall number
- D-0515-2026
- Published
- May 13, 2026
- Risk level
- Class II
- Status
- Ongoing
- Issued by
- U.S. Food and Drug Administration
- Brand
- Ajanta Pharma Ltd.
- Product type
- Prescription & OTC drugs
- Units affected
- 77,376 packs.
- Distribution
- Nationwide
- Made in
- India
- Lot / code info
- Lot#: PA07434, Exp. May 2026.
Products covered by this recall
Duloxetine Delayed-Release Capsules, 60 mg, Rx Only, 30 capsules, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241-099-03
Check your product
The notice names 7 codes you can read straight off the package. Type the one printed on yours and the list below narrows to it.
Lot or batch code
Usually ink-stamped near the seam, the cap or the bottom of the pack.
- PA07434
- 376 packs
Best-by / use-by date
Printed beside the lot code, not on the price sticker.
- May 2026. — 77
- 376 packs
NDC number
On the carton and again on the bottle or blister label.
- 27241-099-03
Package size
Match the net weight or the piece count on the front of the pack.
- 60 mg
- 376 packs
Codes are lifted verbatim from the FDA — Drug enforcement notice. A code that is missing here may still be covered — the official notice is the complete list.
What to do about Potency
Ajanta Pharma Ltd. — The recall concerns the strength or purity of the medicine rather than contamination of it, which changes what you should do about a dose you have already taken.
- Check the lot number on your pack against the codes listed above before you do anything else.
- Report any change in how the medicine is working to FDA MedWatch, which is where most of these signals originate.
- Do not stop a prescription on your own. For most conditions an uncertain dose is safer than no dose while you get advice.
- Call your prescriber or pharmacist and ask whether to swap the lot, re-test, or change nothing.
Getting a replacement supply
Do not let a refund question interrupt your treatment. Deal with the supply first and the money second.
- Call the pharmacy before you run low. They can see which lot they dispensed to you and will usually swap it the same day.
- Insurers do not normally count a recall replacement against a refill limit. If one is refused, ask the pharmacist to call it through as a recall override.
- Over-the-counter products are refunded at the till like any other purchase; the recall notice on your phone is enough to explain the return.
- If the manufacturer runs a direct reimbursement form, it will be linked from the official notice on this page.
Company contact: Ajanta Pharma Ltd. — B-4/5/6 MIDC Industrial Area, Aurangabad
The official notice
This page summarises a notice published by U.S. Food and Drug Administration. The agency notice is the authoritative version — read it before you act, and treat it as the final word if anything here looks different.
Open the FDA — Drug enforcement record U.S. Food and Drug Administration recalls
Questions people ask about this recall
Why was Ajanta Pharma Ltd. prescription & otc drugs recalled?
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals. CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.
How do I know if I have the recalled product?
Match the codes printed on your package against the notice: lot code PA07434, 376 packs; best-by date May 2026. — 77 or 376 packs. If the code on your package is not on that list, your unit is outside the recall.
What should I do with it right now?
Check the lot number on your pack against the codes listed above before you do anything else.
Can I get my money back?
Call the pharmacy before you run low. They can see which lot they dispensed to you and will usually swap it the same day.
Where was the recalled product sold?
It was distributed nationwide.
Related recalls
-
Class II · 18 days ago
Ajanta Pharma USA Inc Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle recall: Failed Dissolution Specifications: below specification
Failed Dissolution Specifications: below specification
-
Class III · last month
Ajanta Pharma USA Inc Fluphenazine Hydrochloride Tablets, USP, 1mg, 100-count bottles recall: Failed impurities/degradation specifications: (OOS) for Organic Impurities
Failed impurities/degradation specifications: (OOS) for Organic Impurities by HPLC (Impurity-A) during testing at the 18 months long term stability…
-
Class II · 4 months ago
Ajanta Pharma USA Inc Fenofibrate Capsules, USP 200 mg recall: CGMP Deviations
CGMP Deviations
-
Class II · 4 months ago
Ajanta Pharma USA Inc Aripiprazole Tablets USP recall: Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled
Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.
-
Class II · 6 months ago
Ajanta Pharma Ltd. Duloxetine Delayed-Release Capsules, 30 mg recall: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term…
-
Class II · 6 months ago
Ajanta Pharma Ltd. Duloxetine Delayed-Release Capsules, 20 mg recall: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term…